Holtec Nuclear postponed its $825 million IPO just before its planned Friday listing, shaking up the US IPO market and drawing attention away from a new $2 billion filing by data center developer Nscale. Holtec had been set for one of the year’s largest offerings, but its sudden decision left investors rethinking the near-term outlook for the sector.
Holtec said in a statement that it "decided to postpone" the IPO after talks with its banking group, citing an "unusual combination of events" that hurt investor confidence in new listings. The registration remains active with the SEC, but there’s no new date for the offering. Reuters and Bloomberg reported that Holtec’s move came as market conditions worsened and investors grew more cautious about large deals, especially in sectors tied to AI and energy, which have seen more volatility lately.
Holtec Nuclear had planned to raise up to $900 million by offering 50 million shares at a price range of $15 to $18, with an expected company valuation of approximately $10.2 billion.
While Holtec stepped back, Nscale (NSCL) filed for an IPO aiming to raise around $2 billion. The UK-based company, which develops global data centers and AI infrastructure, is betting that demand for large-scale tech projects is still strong, even as volatility continues elsewhere. According to Reuters, Nscale reported 1,252% revenue growth in the first half of 2026, but its prospectus does not yet list the number of shares, price range, or expected proceeds.
Biotech IPOs sent mixed signals. Electra Therapeutics (ETRA) priced its upsized IPO at the midpoint, raising $350 million at a $1 billion market cap. The company develops precision medicines targeting SIRP proteins on immune cells. Its shares fell 11.7% by week’s end—a rare drop for a sector that has recently seen strong debuts. Electra’s lead drug, ipsoprubart, is a pan-SIRP monoclonal antibody designed to deplete certain myeloid and T cells, but the market’s reaction suggests investors want more than scientific promise.
American Savings Bank (ASBH) moved in the opposite direction. The Hawaii-based bank priced its upsized IPO at the midpoint, raising $129 million at a $1 billion market cap. With 35 branches across the state, over 120 ATMs, and a digital platform, American Savings Bank ended the week up 9.8%. The result shows that traditional financial services can still attract investors when the fundamentals are clear.
Holtec specifically attributed the IPO postponement to a recent downturn in overall market sentiment, noting that negative investor attitudes have affected both the broader market and the nuclear sector in particular over the past two weeks.
— Holtec International, Company Statement
Orion180 Insurance Group (OIG), which focuses on catastrophe-related homeowners’ insurance, priced below range and raised $240 million at a $1.2 billion market cap. The company says it is the second largest E&S lines homeowners’ insurer in the US, with $601 million in managed premiums over the past year and more than 670,000 policies sold since inception. Still, Orion180 ended the week down 2.8%, showing that size alone does not guarantee post-IPO momentum.
SPAC activity was steady. Haymaker Acquisition V (HYACU) raised $250 million to target industrial and consumer products and services, while Leader’s Advantage Acquisition (LEDRU) secured $150 million for deals in chemicals and healthcare. Five IPOs and three SPACs filed initial paperwork, including two biotechs—Retension Pharmaceuticals (RTSN) and TRex Bio (TRXB)—hoping to attract investors interested in clinical-stage drug developers, even as Electra’s performance casts some doubt.
Market indices reflected the week’s mixed signals. As of 9/17/2026, the Renaissance IPO Index was up 14.7% for the year, ahead of the S&P 500’s 12.5% gain. The Renaissance International IPO Index rose 31.6% year-to-date, doubling the ACWX’s 15.5% increase. Top ETF holdings included Astera Labs, CoreWeave, Galderma, and CATL, highlighting the continued strength of newly public companies in both US and international markets.
This week’s IPO activity showed a market in transition, with investors picking their spots and even large, well-funded offerings struggling without a clear growth story. Holtec Nuclear’s postponement and Electra Therapeutics’ drop underline that capital is not guaranteed. At the same time, Nscale’s bold filing and American Savings Bank’s strong debut show that companies with a convincing case can still draw attention. For those considering going public, the lesson is clear: only the most credible stories are breaking through.
